Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included 154 patients with IBD: 78 UC patients (50.6%)...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Russo |
| منشور في: |
"Consilium Medicum" Publishing house
2021-02-01
|
| سلاسل: | Терапевтический архив |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ter-arkhiv.ru/0040-3660/article/viewFile/64705/47582 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|